Adaptive Biotechnologies (ADPT) Cash & Current Investments (2018 - 2026)

Adaptive Biotechnologies has disclosed Cash & Current Investments across 9 years of filings, most recently posting $218.3 million for Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $218.3 million, up 12.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $218.3 million (up 12.88% YoY), and the FY2025 annual result was $227.0 million, up 2.11% from the prior year.
• Cash & Current Investments came in at $218.3 million for Q1 2026 at Adaptive Biotechnologies, down from $227.0 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $508.1 million in Q3 2022 to a low of $193.4 million in Q1 2025.
• The 5-year median for Cash & Current Investments is $308.9 million (2024), against an average of $320.3 million.
• Peak annual rise in Cash & Current Investments reached 41.11% in 2022, while the deepest fall reached 49.1% in 2022.
• Adaptive Biotechnologies' Cash & Current Investments stood at $498.2 million in 2022, then tumbled by 30.47% to $346.4 million in 2023, then slumped by 35.83% to $222.3 million in 2024, then increased by 2.11% to $227.0 million in 2025, then slipped by 3.81% to $218.3 million in 2026.
• The last three Cash & Current Investments figures came in at $218.3 million (Q1 2026), $227.0 million (Q4 2025), and $212.8 million (Q3 2025), per Business Quant data.